SCHEMBL14257526

SCHEMBL14257526

N#C/N=C(\Nc1ccc(F)cc1Cl)Oc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.43
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
ALOX15 P16050 5/20 0.38
NPSR1 Q6W5P4 2/20 0.38
ALOX12 P18054 1/20 0.38
GPR55 Q9Y2T6 1/20 0.38
POLB P06746 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
PYGL P06737 1/20 0.36
GRM4 Q14833 1/20 0.35
MAPT P10636 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
DHODH Q02127 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14257574 0.87 RAB9A (0.45) ALDH1A1POLBNPC1RAB9AMAPT
SCHEMBL14267805 0.85 SMN1; SMN2 (0.35) KMT2AALDH1A1L3MBTL1NPC1RAB9A
SCHEMBL14257481 0.85 LMNA (0.39) KMT2AALDH1A1NPC1RAB9AMAPT
SCHEMBL14257651 0.85 KMT2A (0.41) KMT2AMEN1ALDH1A1NPSR1POLB
SCHEMBL14258949 0.85 KMT2A (0.41) KMT2AMEN1ALDH1A1NPSR1POLB
SCHEMBL3644300 0.84 KMT2A (0.47) KMT2AMEN1ALDH1A1L3MBTL1NPSR1
SCHEMBL14257534 0.84 KMT2A (0.47) KMT2AMEN1ALDH1A1L3MBTL1NPSR1
SCHEMBL13240726 0.80 ALDH1A1 (0.47) KMT2AMEN1ALDH1A1L3MBTL1NPC1
SCHEMBL14257580 0.79 NPC1 (0.46) KMT2AALDH1A1L3MBTL1NPSR1POLB
SCHEMBL14257545 0.79 FAAH (0.41) KMT2AMEN1ALDH1A1POLBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080076924-A1 Piperazines as P2X7 antagonists ABBOTT LABORATORIES 2008-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076924-A1 Piperazines as P2X7 antagonists P2RX7, P2RX1, P2RX2 KMT2A 3643/4885MEN1 4288/4885ALDH1A1 852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.